SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Scien - Quaterly Results

29 Jul 2022 Evaluate
The sales slipped to Rs. 4231.90 millions for the June 2022 quarter as against Rs. 5087.90 millions during the year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -662.54 millions as compared to Net Loss of Rs. -212.31 millions of corresponding quarter ended June 2021Operating profit Margin for the quarter ended June 2022 slipped to -535.67% as compared to 169.36% of corresponding quarter ended June 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 4231.90 5087.90 -16.82 4231.90 5087.90 -16.82 19790.03 18575.66 6.54
Other Income 74.65 116.86 -36.12 74.65 116.86 -36.12 1234.85 889.96 38.75
PBIDT -535.67 169.36 -416.29 -535.67 169.36 -416.29 2001.15 2763.16 -27.58
Interest 260.17 180.91 43.81 260.17 180.91 43.81 742.41 653.39 13.62
PBDT -795.84 -11.55 6790.39 -795.84 -11.55 6790.39 1258.74 2109.77 -40.34
Depreciation 242.96 266.36 -8.79 242.96 266.36 -8.79 1043.66 993.42 5.06
PBT -1038.80 -277.91 273.79 -1038.80 -277.91 273.79 215.08 1116.35 -80.73
TAX -376.26 -65.60 473.57 -376.26 -65.60 473.57 -1586.80 333.95 -575.16
Deferred Tax -376.26 -65.60 473.57 -376.26 -65.60 473.57 -2.09 123.77 -101.69
PAT -662.54 -212.31 212.06 -662.54 -212.31 212.06 1801.88 782.40 130.30
Equity 898.04 897.17 0.10 898.04 897.17 0.10 897.90 896.80 0.12
PBIDTM(%) -12.66 3.33 -480.27 -12.66 3.33 -480.27 10.11 14.88 -32.02

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×